A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians
- 646 Downloads
To the Editor,
A recent, systematic, qualitative, review by Murphy et al.  has provided a complete overview of the available data on persistence and adherence to hormonal therapy for breast cancer, as well as an extensive description of their determinants. This review demonstrates that treatment intakes are largely suboptimal. It also illustrates the heterogeneity of available studies, with treatment discontinuation rates ranging from 31 to 73 % over the treatment period. This wide range of values may limit the usefulness of raw data for clinicians. In order to provide measures clinicians might use effectively, we conducted a meta-regression analysis  that summarizes results on adherence and persistence to hormonal therapy, based on the data rigorously selected in the review by Murphy et al. This meta-regression analysis was conducted moreover to assess the different sources of variability in measurements of persistence.
We reviewed the 29 studies selected in the comprehensive...
KeywordsBreast Cancer Tamoxifen Aromatase Inhibitor Treatment Adherence Adjuvant Hormonal Therapy
We are indebted to Arianne Dorval for proofreading the English manuscript.
Conflict of interest
- 8.Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1–48Google Scholar
- 17.Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2012) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. doi: 10.1097/coc.0b013e3182436ec1
- 21.Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H (2009) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in earlystage breast cancer. J Clin Oncol 28(14):2423–2429Google Scholar
References for Rebuttal letter
- 2.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. (2012) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: a randomised trial. LancetGoogle Scholar